CHEMBL202 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Dihydrofolate reductase shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00374. Start with non-small cell lung carcinoma, then reuse UniProt P00374 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with non-small cell lung carcinoma, then reuse UniProt P00374 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs

Open source guide

Disease program

non-small cell lung carcinoma

Dihydrofolate reductase shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with non-small cell lung carcinoma because it currently carries approved-linked support. Linked drugs include METHOTREXATE, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Approved-linked Open Targets-ready proxy 6 linked drugs

Open disease block

Protein anchor

Dihydrofolate reductase

Review this target as Dihydrofolate reductase, mapped to UniProt P00374. Sequence length is 187 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P00374 Protein 187 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dihydrofolate reductase as ChEMBL target CHEMBL202, mapped to UniProt P00374. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Dihydrofolate reductase

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL202

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P00374

Dihydrofolate reductase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dihydrofolate reductase is the right protein anchor across sources, using UniProt P00374 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-small cell lung carcinoma is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Dihydrofolate reductase
Target Type	SINGLE PROTEIN
Organism	Homo sapiens
UniProt	P00374

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Dihydrofolate reductase
UniProt Accession	P00374
Component Type	Protein
Sequence Length	187 aa

Dihydrofolate reductase

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 4:50 AM KST As of · Sep 13, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Dihydrofolate reductase, mapped to UniProt P00374. Sequence length is 187 aa.

Mapped IDP00374

Review nameDihydrofolate reductase

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Dihydrofolate reductase shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved

non-small cell lung carcinoma

6 linked drugs · 6 direct · 6 efficacy

Linked drugMETHOTREXATE

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Linked drugPEMETREXED MONOHYDRATE

Approved-linked Approved

mesothelioma

5 linked drugs · 5 direct · 5 efficacy

Linked drugMETHOTREXATE

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Linked drugPEMETREXED MONOHYDRATE

Approved-linked Approved

breast cancer

4 linked drugs · 4 direct · 4 efficacy

Linked drugMETHOTREXATE

Linked drugMETHOTREXATE SODIUM

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Approved-linked Approved

cancer

4 linked drugs · 4 direct · 4 efficacy

Linked drugMETHOTREXATE

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Linked drugPRALATREXATE

Approved-linked Approved

lung cancer

4 linked drugs · 4 direct · 4 efficacy

Linked drugMETHOTREXATE SODIUM

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Linked drugPRALATREXATE

Approved-linked Approved

neoplasm

4 linked drugs · 4 direct · 4 efficacy

Linked drugMETHOTREXATE

Linked drugPEMETREXED

Linked drugPEMETREXED DISODIUM

Linked drugPRALATREXATE

Source · ChEMBL drug mechanism + indication proxy Freshness · Sep 14, 2026, 4:50 AM KST As of · Sep 13, 2026

ChEMBL target record ↗

Review Cue

How to read disease relevance

Start review with non-small cell lung carcinoma because it currently carries approved-linked support. Linked drugs include METHOTREXATE, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-small cell lung carcinoma

Strongest levelApproved-linked

Block modeOpen Targets-ready proxy

Clinical Profile

Clinical Phase Distribution

18

Approved

2

Phase III

10

Phase II

1

Phase I

Assay Mix

Activity Type Distribution

IC501,546.0

KI512.0

KD86.0

Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL ID	pChEMBL	Type	Value (nM)	Phase
CHEMBL305177	11.0	Ki	0.01	Preclinical
CHEMBL34259	11.0	Ki	0.01	Approved
CHEMBL1201746	10.87	Ki	0.0134	Approved
CHEMBL7492	10.6	Ki	0.025	Clinical
CHEMBL390990	10.47	Ki	0.034	Preclinical
CHEMBL119	10.4	Ki	0.04	Approved
CHEMBL388501	10.11	Ki	0.077	Preclinical
CHEMBL171765	10.0	Ki	0.1	Preclinical
CHEMBL170760	10.0	Ki	0.1	Preclinical
CHEMBL135937	10.0	Kd	0.1	Preclinical

Distribution

pChEMBL Value Distribution

187

5.0

332

5.5

260

6.0

190

6.5

165

7.0

154

7.5

141

8.0

54

8.5

16

9.0

12

9.5

pChEMBL

Approved Drugs

TERIFLUNOMIDE

CHEMBL973

Approved 2012

Properties Compare Identifier

PRALATREXATE

CHEMBL1201746

Approved 2009

Properties Compare Identifier

PEMETREXED

CHEMBL225072

Approved 2004

Properties Compare Identifier

RALTITREXED

CHEMBL225071

Approved 1996

Properties Compare Identifier

TRIMETREXATE

CHEMBL119

Approved 1993

Properties Compare Identifier

TRIMETHOPRIM

CHEMBL22

Approved 1973

Properties Compare Identifier

METHOTREXATE

CHEMBL34259

Approved 1953

Properties Compare Identifier

PYRIMETHAMINE

CHEMBL36

Approved 1953

Properties Compare Identifier

SULFADIAZINE

CHEMBL439

Approved 1941

Properties Compare Identifier

Assay Landscape

453

Total Assays

1,134

Tested Compounds

4

Assay Types

Binding — 423 assays, 1,134 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
single protein format	353	1,042	6.4
cell-based format	40	57	7.5
assay format	30	35	7.0

ADME — 16 assays, 163 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
single protein format	12	80	6.6
assay format	2	35	5.0
cell-based format	2	48	6.1

Functional — 12 assays, 1 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
assay format	11	0	—
cell-based format	1	1	4.7

Toxicity — 2 assays, 40 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
assay format	1	6	—
cell-based format	1	34	4.5

CHEMBL202 Target Snapshot

Research home keeps recent targets

Switch target

Frame the target before identity details

Cross-source identity

Start with the right source

Basic Information

Next Actions

UniProt Target Context

How to read this target

Disease Relevance & Evidence Level

How to read disease relevance

Clinical Phase Distribution

Activity Type Distribution

Top Inhibitors (by pChEMBL)

pChEMBL Value Distribution

Approved Drugs

Assay Landscape

Confidence Score Distribution